KVUE earnings analysis
What we found in KVUE's 10-Q: the parts that mattered, the offsets in the same document, and what the company said about what comes next.
Our reading of the filing · Free to read, no account needed
Kenvue reported Q1 2026 results with net sales reaching $3.91 billion, marking a 4.5% increase from $3.74 billion in Q1 2025. Gross margin improved to 58.9%, while diluted EPS was slightly below consensus at $0.25 against an estimate of $0.26. The management highlighted ongoing efficiencies and cost savings amidst challenges related to an impending merger with Kimberly-Clark and external economic pressures.
The parts that mattered.
Pulled out of the filing itself, with the figures the company reported.
- Revenue Growth
- Net sales increased by $168 million to $3.91 billion, a 4.5% rise compared to $3.74 billion in Q1 2025.
- Gross Margin Expansion
- Gross profit margin improved by 90 basis points to 58.9% from 58.0% in the prior year.
- Operating Income Surged
- Operating income increased by 37.5% to $767 million from $558 million in Q1 2025.
- Restructuring Savings
- Adjusted operating income in total segments grew by 21.7%, influenced by restructuring cost efficiencies.
- Improved Skin Health Sales
- Skin Health and Beauty segment grew by $82 million, an 8.4% increase year-over-year.
- Strong Essential Health Performance
- Essential Health segment net sales rose by $54 million, or 4.9% compared to Q1 2025.
And the other side of it.
The offsets in the same document — the things a summary that only listed the good news would have left out.
- Pending Merger Costs
- The pending acquisition by Kimberly-Clark may disrupt operations, incurring significant advisory and integration costs.
- Market Volatility Impact
- The ongoing conflict in the Middle East could create further economic uncertainty and operational challenges.
- Inflation and Supply Chain Pressures
- Rising inflation and recent tariffs are expected to increase supply chain costs by approximately $90 million annually.
What they reported.
What the company itself reported, taken out of the document.
- Earnings per share
- $0.25
- Gross margin
- 58.9%
- Operating margin
- 19.6%
- Segment
- Self Care: $1.699B
- Segment
- Skin Health and Beauty: $1.059B
- Segment
- Essential Health: $1.151B
What they said about what is next.
The Company will not provide forward-looking guidance due to ongoing pending acquisition.
The filing reads about the same as the one before it.
What came before.
- 10-K · February 20, 2026
- Kenvue positions itself as the world’s largest pure‑play consumer health company with Net sales of $15.1 billion in fiscal 2025 and a portfolio spanning Self Care, Skin Health & Beauty, and Essential Health. The company…
- 10-Q · August 7, 2025
- Kenvue posted Q2 net sales of $3,839 million, down $161 million versus Q2 2024 ($4,000 million), but delivered strong margin recovery and earnings: gross profit of $2,261 million and operating income of $692 million…
- 10-Q · August 6, 2024
- Kenvue’s GAAP Q2 results show essentially flat revenue at $4,000 million (down $11 million vs $4,011 million a year earlier) and an improved gross profit of $2,365 million (up $140 million), lifting gross margin to…
- 10-Q · August 2, 2023
- Kenvue reported quarterly net sales of $4,011 million, up $207 million versus the prior-year quarter, but saw net income and diluted EPS decline to $430 million and $0.23 (versus $604 million and $0.35). The company…
This is our reading of a public filing, not the filing. Read the original on SEC.gov · Educational only. Nothing here is investment advice.
Read the next one first.
We read every filing KVUE makes the day it lands, and put it next to what the options market did about it. Members get both, and an alert when a filing arrives.
Cancel anytime · Month to month · Switch tiers whenever